On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered into an agreement to support the supply of Dynavax’s CpG 1018 advanced adjuvant to be used in approved COVID-19 vaccines developed by CEPI grantees.